Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Sep;64(3):593–597. doi: 10.1038/bjc.1991.356

A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.

J L Mansi 1, A de Graeff 1, D R Newell 1, J Glaholm 1, D Button 1, M O Leach 1, G Payne 1, I E Smith 1
PMCID: PMC1977661  PMID: 1911204

Abstract

Lonidamine is a substituted indazole carboxylic acid with a unique mechanism of action and early clinical studies have reported anti-tumour activity. In a phase II study 32 patients with previously treated advanced breast cancer were given Lonidamine in a daily divided oral dose of 600 mg. Of 28 patients evaluable for response, three (11%) achieved a partial response (4-24+ months) and three (11%) a minor response. Two patients have stable disease (greater than 3 months) and 20 progressed. Toxicity was very mild. Sixteen (53%) of 31 patients had myalgia which lasted a median of 2 weeks. This was investigated with nuclear magnetic resonance spectroscopy in four patients but the changes were unrelated to the degree of myalgia. No other major side-effect was seen, and no dose reduction was required. Lonidamine pharmacokinetics have been investigated in 17 patients 1 month after the start of therapy. Lonidamine was detected in the plasma of all patients, but there was no clear relationship between Lonidamine levels and clinical response or toxicity. Lonidamine appears to be active against advanced breast cancer and its low toxicity would allow combination studies with chemotherapy.

Full text

PDF
593

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Band P. R., Deschamps M., Besner J. G., Leclaire R., Gervais P., De Sanctis A. Phase I toxicologic study of Lonidamine in cancer patients. Oncology. 1984;41 (Suppl 1):56–59. doi: 10.1159/000225887. [DOI] [PubMed] [Google Scholar]
  2. Band P. R., Maroun J., Pritchard K., Stewart D., Coppin C. M., Wilson K., Eisenhauer E. A. Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Cancer Treat Rep. 1986 Nov;70(11):1305–1310. [PubMed] [Google Scholar]
  3. Besner J. G., Leclaire R., Band P. R., Deschamps M., De Sanctis A. J., Catanese B. Pharmacokinetics of Lonidamine after oral administration in cancer patients. Oncology. 1984;41 (Suppl 1):48–52. doi: 10.1159/000225885. [DOI] [PubMed] [Google Scholar]
  4. DeAngelis L. M., Currie V. E., Kim J. H., Krol G., O'Hehir M. A., Farag F. M., Young C. W., Posner J. B. The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J Neurooncol. 1989 Sep;7(3):241–247. doi: 10.1007/BF00172917. [DOI] [PubMed] [Google Scholar]
  5. Eleff S., Kennaway N. G., Buist N. R., Darley-Usmar V. M., Capaldi R. A., Bank W. J., Chance B. 31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle. Proc Natl Acad Sci U S A. 1984 Jun;81(11):3529–3533. doi: 10.1073/pnas.81.11.3529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Floridi A., Paggi M. G., D'Atri S., De Martino C., Marcante M. L., Silvestrini B., Caputo A. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res. 1981 Nov;41(11 Pt 1):4661–4666. [PubMed] [Google Scholar]
  7. Floridi A., Paggi M. G., Marcante M. L., Silvestrini B., Caputo A., De Martino C. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst. 1981 Mar;66(3):497–499. [PubMed] [Google Scholar]
  8. Gadian D., Radda G., Ross B., Hockaday J., Bore P., Taylor D., Styles P. Examination of a myopathy by phosphorus nuclear magnetic resonance. Lancet. 1981 Oct 10;2(8250):774–775. doi: 10.1016/s0140-6736(81)90186-0. [DOI] [PubMed] [Google Scholar]
  9. Giannotti P., Ambrogi F., Ciottoli G. B. Lonidamine plus adriamycin versus adriamycin alone in the adjuvant treatment of recurrent papillary carcinomas of the urinary bladder. Oncology. 1984;41 (Suppl 1):104–107. doi: 10.1159/000225896. [DOI] [PubMed] [Google Scholar]
  10. Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  11. Leclaire R., Besner J. G., Band P., Mailhot S., Gervais P., De Sanctis A., Deschamps M., Liverani L. High-performance liquid chromatography of lonidamine in human plasma and urine. J Chromatogr. 1983 Oct 14;277:427–432. doi: 10.1016/s0378-4347(00)84871-9. [DOI] [PubMed] [Google Scholar]
  12. Pronzato P., Amoroso D., Bertelli G., Conte P. F., Cusimano M. P., Ciottoli G. B., Gulisano M., Lionetto R., Rosso R. Phase II study of lonidamine in metastatic breast cancer. Br J Cancer. 1989 Feb;59(2):251–253. doi: 10.1038/bjc.1989.51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Radda G. K., Taylor D. J., Arnold D. L. Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy. Biochem Soc Trans. 1985 Aug;13(4):654–654. doi: 10.1042/bst0130654. [DOI] [PubMed] [Google Scholar]
  14. Radda G. K. The use of NMR spectroscopy for the understanding of disease. Science. 1986 Aug 8;233(4764):640–645. doi: 10.1126/science.3726553. [DOI] [PubMed] [Google Scholar]
  15. Segre G., Catanese B. Pharmacokinetics of lonidamine. Chemotherapy. 1981;27 (Suppl 2):77–84. doi: 10.1159/000238047. [DOI] [PubMed] [Google Scholar]
  16. Sharp J. C., Leach M. O. Conformal NMR spectroscopy: accurate localization to noncuboidal volumes with optimum SNR. Magn Reson Med. 1989 Sep;11(3):376–388. doi: 10.1002/mrm.1910110312. [DOI] [PubMed] [Google Scholar]
  17. Silvestrini B. Basic and applied research in the study of indazole carboxylic acids. Chemotherapy. 1981;27 (Suppl 2):9–20. doi: 10.1159/000238040. [DOI] [PubMed] [Google Scholar]
  18. Weinerman B. H., Eisenhauer E. A., Besner J. G., Coppin C. M., Stewart D., Band P. R. Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study. Cancer Treat Rep. 1986 Jun;70(6):751–754. [PubMed] [Google Scholar]
  19. Young C. W., Currie V. E., Kim J. H., O'Hehir M. A., Farag F. M., Kinahan J. E. Phase I and clinical pharmacologic evaluation of Lonidamine in patients with advanced cancer. Oncology. 1984;41 (Suppl 1):60–65. doi: 10.1159/000225888. [DOI] [PubMed] [Google Scholar]
  20. Zupi G., Greco C., Laudonio N., Benassi M., Silvestrini B., Caputo A. In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin. Anticancer Res. 1986 Sep-Oct;6(5):1245–1249. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES